Suzetrigine (VX-548) represents a landmark advancement in analgesic pharmacology — the first selective Nav1.8 sodiumchannel blocker to achieve regulatory approval. Approved by the U.S. Food and Drug Administration (FDA) in January 2025under the brand name Journavx, this molecule provides effective pain relief without engaging the μ-opioid receptor pathway,thereby circumventing the addiction, respiratory depression, and tolerance liabilities that have defined the opioid crisis. Thisresearch synthesizes the physical, engineering, and mathematical frameworks that govern Suzetrigine's behavior withinhuman cellular systems.
Khaled Aldhufri (Sun,) studied this question.
Synapse has enriched 5 closely related papers on similar clinical questions. Consider them for comparative context: